Pain relief agents

Details Pain relief agents Pain relief agents

2003-11-05

2010-06-29

Swartz, Rodney P. (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

C424S009100, C424S009200, C424S184100, C424S185100, C424S243100, C530S300000, C530S350000, C536S023100, C536S023700

Reexamination Certificate

active

07744906

ABSTRACT:
The present invention concerns the use of a heat shock polypeptide and/or an encoding nucleic acid sequence in the manufacture of a medicament for use in the relief of pain. In particular the invention concerns the use of chaperonin. The invention further provides methods of relieving pain medicaments containing the heat shock polypeptides.

REFERENCES:
patent: 4440859 (1984-04-01), Rutter et al.
patent: 4530901 (1985-07-01), Weissmann
patent: 4582800 (1986-04-01), Crowl
patent: 4677063 (1987-06-01), Mark et al.
patent: 4678751 (1987-07-01), Goeddel
patent: 4704362 (1987-11-01), Itakura et al.
patent: 4710463 (1987-12-01), Murray
patent: 4757006 (1988-07-01), Toole, Jr. et al.
patent: 4766075 (1988-08-01), Goeddel et al.
patent: 4810648 (1989-03-01), Stalker
patent: 5856305 (1999-01-01), Lucietto et al.
patent: 6117421 (2000-09-01), Morton et al.
patent: WO 96/16083 (1996-05-01), None
patent: WO 99/35270 (1999-07-01), None
patent: WO 01/04344 (2001-01-01), None
patent: WO 02/40037 (2002-05-01), None
patent: WO 02/40037 (2002-05-01), None
patent: WO 02/40038 (2002-05-01), None
patent: WO 02/40517 (2002-05-01), None
patent: 2009/106819 (2009-09-01), None
B. Henderson et al, “Molecular Chaperones and Disease”, Inflammation Research, vol. 45, No. 4, (1996), pp. 155-158.
F. J. Andrews, et al., “Effect of iron chelation on inflammatory joint disease”, Annals of the Rheumatic Diseases, 46, 327-333, (1987).
P. N. Baird, et al., “Cloning and Sequence Analysis of the 10 kDa Antigen Gene ofMycobacterium tuberculosis”, Journal of General Microbiology 135, 931-939, (1989), XP-008005161.
P. N. Baird, et al., “A major antigen fromMycobacterium tuberculosiswhich is homologous to the heat shock proteins groES fromE.coliand the htpA gene product ofCoxiella burneti”, Nucleic Acids Research, vol. 16, No. 18 p. 9047, (1988), XP-001074008.
M. Bassan, et al., “The identification of secreted heat shock 60 -like protein from rat glial cells and a human neuroblastoma cell line”, Neuroscience Letters 250, 37-40, (1998).
J. T. Beech, et al., “CD4+Th2 Cells Specific for Mycobacterial 65-kilodalton Heat Shock Protein Protect Against Pristane-Induced Arthritis”, The Journal of Immunology, 159, 3692-3697, (1997).
K. Bethke, et al., “Different Efficiency of Heat Shock Proteins (HSP) to Activate Human Monocytes and Dendritic Cells: Superiority of HSP60”, The Journal of Immunology, 169, 6141-6148, (2002).
V. L. D. Bonato, et al, “Identification and Characterization of Protective T Cells in hsp65 DNA-Vaccinated andMycobacterium tuberculosis-Infected Mice”, Infection and Immunity, vol. 66, No. 1, pp. 169-175, Jan. 1998.
A. C. Cavanagh, “Identification of early pregnancy factor as chaperonin 10: implications for understanding its role”, Reviews of Reproduction, 1, 28-32, (1996).
H. Chiu, et al., “Differential Induction of Heme Oxygenase- 1 in Macrophages and Hepatocytes during Acetaminophen-Induced Hepatotoxicity in the Rat: Effects of Hemin and Biliverdin”, Toxicology and Applied Pharmacology 181, 106-115, (2002).
A. R. M. Coates, et al., “Chaperonins in Health and Disease”, Annals of NY Academy of Sciences, 851, 48-52, (1998).
A. R. M. Coates, et al., “The Unfolding Story of the Chaperonins”, Biotechnology and Genetic Engineering Reviews, vol. 16, pp. 393-405, Apr. 1999.
A. R. M. Coates, “Immunological Aspects of Chaperonins”, The Chaperonins, Academic Press 267-296, (1996).
I. R. Cohen, “Peptide therapy for Type I diabetes: the immunological homunculus and the rationale for vaccination”, Diabetologia, 45, 1468-1474, (2002).
N. Cranswick, et al., “Paracetamol Efficacy and Safety in Children: the First 40 Years”, American Journal of Therapeutics, 7, 135-141, (2000).
H. L. F. Currey, et al., “Suppression of Adjuvant Disease in the Rat by Heterologous Antilymphocyte Globulin”, J. Exp. Med., 127, 185-203, (1968).
D. Elias, “Induction and therapy of autoimmune diabetes in the non-obese diabetic (NOD/Lt) mouse by a 65-kDa heat shock protein”, Proc. Natl. Acad. Sci. USA, vol. 87, pp. 1576-1580, Feb. 1990.
C. El-Khoury, et al., “Attenuation of Neuropathic Pain by Segmental and Supraspinal Activation of the Dorsal Column System in Awake Rats”, Neuroscience vol. 112, No. 3, pp. 541-553, (2002).
S. B. Flohé, et al., “Human Heat Shock Protein 60 Induces Maturation of Dendritic Cells Versus a Th1-Promoting Phenotype”, The Journal of Immunology, 170, 2340-2348, (2003).
J. S. Friedland, et al., “Mycobacterial 65-kD heat shock protein induces release of proinflammatory cytokines from human monocytic cells”, Clin Exp Immunol, 91, 58-62, (1993).
A. Frisk, et al., “GroEL Heat Shock Protein ofHaemophilus ducreyi: Association with Cell Surface and Capacity To Bind to Eukaryotic Cells”, Infection and Immunity, vol. 66, No. 3, pp. 1252-1257, Mar. 1998.
G. Furness, “A breath of fresh air”, Scrip Magazine, Pharmaceutical issues in perspective, pp. 10-13, Nov. 2004.
S. E. Girardin, et al., “Intracellular vs extracellular recognition of pathogens—common concepts in mammals and flies”, Trends in Microbiology, vol. 10, No. 4, pp. 193-199, Apr. 2002.
A. P. Gobert, et al., “Helicobacter pyloriHeat Shock Protein 60 Mediates Interleukin-6 Production by Macrophages via a Toll-like Receptor (TLR)-2-, TLR-4-, and Myeloid Differentiation Factor 88-independent Mechanism”, The Journal of Biological Chemistry, vol. 279, No. 1 pp. 245-250, Jan. 2, 2004.
F. Goulhen, et al., “Subcellular Localization and Cytotoxic Activity of the GroEL-Like Protein Isolated fromActinobacillus actinomycetemcomitans”, Infection and Immunity, vol. 66, No. 11, pp. 5307-5313, Nov. 1998.
C. Habich, et al., “Different heat shock protein 60 species share pro-inflammatory activity but not binding sites on macrophages”, FEBS Letters, 533, 105-109, (2003).
B. Henderson, et al., “Molecular chaperones and disease”, Inflammation Research, 45, (155-158), 1996.
W. S. Hills, “Areas of Emerging Interest in Analgesia: Cardiovascular Complications”, American Journal of Therapeutics, 9, 259-269, (2002).
S. Jindal, “Heat Shock Proteins in Infections and Immunity”, Heat Shock Proteins conference handout, Cambridge Center Marriott, Cambridge, MA, Sep. 29-30, 1994.
S. A. Kanaan, et al., “Endotoxin-induced local inflammation and hyperalgesia in rats and mice: a new model for inflammatory pain”, Pain, 66, 373-379, (1996).
Kirby, et al., “Potent Bone-resorbing Mediator ofActinobacillus actinomycetemcomitanshomologous to the Molecular Chaperone GroEL”, J Clin Invest 96, 1185-1194, (1995).
A. Kol, et al., “Chlamydial Heat Shock Protein 60 Localizes in Human Atheroma and Regulates Macrophage Tumor Necrosis Factor-α and Matrix Metalloproteinase Expression”, Circulation, 98, 300-307 (1998).
A. Kol, et al., “Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages”, The Journal of Clinical Investigation, vol. 103, No. 4, 571-577, Feb. 1999.
T. H. Kong, et al., “Mycobacterium tuberculosisexpresses two chaperonin-60 homologs”, Proc. Natl. Acad. Sci. USA, vol. 90, 2608-2612, Apr. 1993 Microbiology.
R. A. Laskey, et al., “Nucleosomes are assembled by an acidic protein which binds histones and transfers them to DNA”, Nature, vol. 275, 416-420, Oct. 5, 1978.
J. Lewthwaite, et al., “Rhizobium leguminosarumchaperonin 60.3, but not chaperonin 60.1, induces cytokine production by human monocytes: activity is dependent on interaction with cell surface CD14”, Cell Stress and Chaperonins, 7 (2) 130-136, (2002).
J. Lewthwaite, et al., “Circulating Human Heat Shock Protein 60 in the Plasma of British Civil Servants”, Circulation, 106

Affiliated with

Also associated with

Rating

Pain relief agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pain relief agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pain relief agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4190674